Navigation Links
IDEXX Laboratories Announces Fourth Quarter and Full Year Results
Date:1/30/2009

ting and integration costs is not representative of ongoing operations and is not indicative of future performance. Specific acquisition-related discrete costs do not include amortization expense related to acquired intangible assets. We applied the statutory income tax rates of the applicable tax jurisdictions to calculate the after-tax impact of these discrete items. (3) We believe that the impact of the disposition of certain pharmaceutical product lines and the related restructuring of the remaining pharmaceutical business in the fourth quarter of 2008 is not indicative of future performance because significant transactions and related costs of a similar nature are not likely to recur within a reasonable period. In the fourth quarter of 2008 we completed a transaction to sell our ACAREXX and SURPASS pharmaceutical products and a product currently under development, which were a part of our CAG segment, and subsequently restructured the remaining pharmaceutical business. (4) We believe that certain significant discrete income tax items create impacts on financial measures that are not indicative of future performance because the items are not likely to recur within a reasonable period. For 2008, the separately identified discrete income tax benefit was due to a reduction in international deferred tax liabilities due to lower anticipated international tax rates. (5) The sum of the individual items may not equal the non-GAAP measurement due to rounding of the individual items in this presentation.


    IDEXX Laboratories, Inc. and Subsidiaries
    Segment Information
    Amounts in thousands (Unaudited)

                                 Three Months Ended      Twelve Months Ended
                                 December    December    December    December
                                     31,      
'/>"/>
SOURCE IDEXX Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related medicine news :

1. IDEXX Laboratories to Release 2008 Fourth Quarter and Full-Year Financial Results
2. IDEXX Laboratories Names William Brown Corporate Vice President
3. IDEXX Laboratories to Present at William Blair 28th Annual Growth Stock Conference
4. IDEXX Laboratories to Release 2008 First Quarter Financial Results
5. IDEXX Laboratories Announces Increase in Share Repurchase Program
6. IDEXX Laboratories Announces Fourth Quarter Results
7. IDEXX Laboratories to Release 2007 Fourth Quarter and Full-Year Financial Results
8. IDEXX Laboratories to Present at JPMorgan Healthcare Conference
9. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009
10. Bedford Laboratories(TM) to Begin Shipping Irinotecan HCl Injection
11. Metametrix Announces Acquisition of Accu-Chem Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... 01, 2015 , ... Stress comes in many different forms ... changes can lead to very serious, life-altering events. Fortunately nature offers a range ... supplement manufacturer MediHerb has coupled therapeutic doses of Rhodiola and Schisandra ...
(Date:9/1/2015)... Seattle, WA (PRWEB) , ... September 01, 2015 , ... ... despite increasing awareness of societal issues and needs. Money for Good 2015, released today ... for solving it. There’s an annual potential to mobilize up to $22B in new ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... prevent different malignancies. Some options for cancer treatment are available belonging to ... distinctive approach is necessary for effective treatment. Several molecules have been discovered ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Splashtop Business for Remote Support , a solution optimized for MSPs and ... with the escalating renewal prices and inadequate customer services of existing remote support ...
(Date:9/1/2015)... TX (PRWEB) , ... September 01, 2015 , ... ... that it is now offering the MonaLisa Touch® , an innovative vaginal ... The MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a condition ...
Breaking Medicine News(10 mins):Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3
... ... ... York College of Osteopathic Medicine (NYCOM) at NYIT announced programs now underway in connection ... 2009 from the U.S. Health Resources and Services Administration (HRSA). , , ,The ...
... a vertebral fracture, states an article in CMAJ ... only) http://www.cmaj.ca/embargo/cmaj090710.pdf Height loss is common ... Causes include changes in the curvature of the spine, ... adults have back pain at any time. Diagnosing these ...
... researchers from the Harvard School of Public Health (HSPH) in ... Evaluation at the University of Washington estimates that smoking, high ... reduce life expectancy in the U.S. by 4.9 years in ... study to look at the effects of those four preventable ...
... , ... , ... ... "The health care reform legislation passed by the United States House of Representatives yesterday is ...
... March 22 Richard J. Statuto , President and Chief Executive Officer of Bon Secours Health System Inc., announces the appointment of ... regional health system. , ... , , ... ...
... (the Company), (Pink Sheets: EPGL), ( www.eparent.com ), the parent company of Exceptional Parent ( EP ) magazine, has announced that as the first quarter of 2010 ... ... ... ...
Cached Medicine News:Health News:New York College of Osteopathic Medicine (NYCOM) at NYIT Awarded $1 Million Federal Grant 2Health News:New York College of Osteopathic Medicine (NYCOM) at NYIT Awarded $1 Million Federal Grant 3Health News:4 preventable risk factors reduce life expectancy in US and lead to health disparities 2Health News:4 preventable risk factors reduce life expectancy in US and lead to health disparities 3Health News:Statement of Ralph B. Everett, President and CEO, Joint Center for Political and Economic Studies, on House Passage of Health Reform Legislation 2Health News:Statement of Ralph B. Everett, President and CEO, Joint Center for Political and Economic Studies, on House Passage of Health Reform Legislation 3Health News:Bon Secours Charity Health System Appoints Philip A. Patterson As CEO 2Health News:Bon Secours Charity Health System Appoints Philip A. Patterson As CEO 3Health News:Bon Secours Charity Health System Appoints Philip A. Patterson As CEO 4Health News:EP Global Communications, Inc. Closes First Quarter With Positive Developments 2Health News:EP Global Communications, Inc. Closes First Quarter With Positive Developments 3Health News:EP Global Communications, Inc. Closes First Quarter With Positive Developments 4
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015  Dr. Cindy ... Labs , the cannabis testing subsidiary of DigiPath, Inc. ... Group about the lack of consistency in today,s ... online resource for medical cannabis information, she explained that ... because their lack of uniform requirements makes standardization impossible. ...
(Date:9/1/2015)... 1, 2015   Alpha Imaging LLC , a leading distributor ... announced today that they have been awarded exclusive rights to ... in Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales ... Ohio , Indiana , ... , West Virginia , Delaware ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3Alpha Imaging Expands Shimadzu Territory 2
... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: